Jump to Main Contents
研究所ロゴ

Home > Division of Cancer RNA Research

Division of Cancer RNA Research

News

Sep. 18, 2024
Kazuki Nishimura's paper has been published in NPJ Precision Oncology!
Sep. 18, 2024
Our research proposal, -Precision stratified treatment based on individual differences due to retrotransposon-based insertion polymorphisms- has been chosen for funding by AMED. PI: Akihide Yoshimi
Sep. 15, 2024
Ryoichi Maenosono received the Chairman's Award at The 100th Annual Meeting for the Osaka Society for Dialysis Therapy!!
Sep. 14, 2024
Ryoichi Maenosono had an oral presentation at The 60th Annual Congress of the Japan Society for Transplantation!!
Sep. 1, 2024
Moritoshi Sakamoto joined our team as an observership visitor!
Aug. 30, 2024
Satoshi Kaito's paper has been published in Nature Communications!
Aug. 21, 2024
Masahiko Ajiro delivered an invited talk at the Okayama Cardiovascular Conference!!
Jul. 31, 2024
Rei Kudo's project, 'Preclinical Study of a Novel Nucleic Acid Medicine Therapy for Cancer,' has been selected for the Grant-in-Aid for Research Activity Start-up!
Jul. 29, 2024
Junko Mukohyama's paper has been published in Anticancer Research.
Jul. 12, 2024
Rei Kudo presented a poster at the 32nd Annual Meeting of the Japanese Breast Cancer Society.
more

Our Research Interest


Our studies have been focused on how RNA processing including RNA splicing is altered in cancer and functionally drives cancer initiation and maintenance. The advent of high-throughput transcriptome sequencing has provided a wealth of information on RNA splicing on a genome-wide scale. It is now understood that > 95% of human genes are subject to alternative splicing. RNA splicing is considered to be a major mediator of proteome diversity through its ability to generate multiple transcripts with differing amino acid sequences from a single gene. The discovery of recurrent mutations in components of the RNA-splicing machinery in 2011 further highlighted the importance of aberrant splicing in cancer as well as a potential therapeutic vulnerability for cells bearing these mutations. Despite the major advances in our understanding of the genomics, molecular biology and therapeutic implications of altered RNA processing in cancer, the full contribution of aberrant RNA splicing to cancer pathogenesis has not been fully elucidated. Our aim is to contribute to the full understanding of the pathogenic roles of altered RNA processing in a variety of cancers and to the development of therapeutically efficacious and safe strategies to improve the outcome of cancer patients.
wordle2.png
(Figure was made by using Wordle based on our recent papers)